The reverse merger will likely result in massive dilution for current INM holders, with the combined company effectively a Mentari entity at a $125M valuation. Traders should monitor the S-4 for the exchange ratio and the special meeting date. The stock may trade down as the dilutive structure becomes clear, though near-term volatility could arise from the reverse split and PIPE speculation.
Price Chart
Executive Summary
InMed Pharmaceuticals entered into Amendment No. 1 to its merger agreement with Mentari Therapeutics, clarifying deal sequencing, tax treatment, and the impact of pre-closing financing on the exchange ratio. The company also filed an S-4 registration statement for the all-stock reverse merger, expected to close in Q4 2026. The transaction effectively transforms InMed into a migraine-focused biotech (Mentari) with a $125M enterprise value for Mentari, but InMed's current shareholders face massive dilution and a reverse stock split to maintain Nasdaq listing.
Key Financial Metrics
Key Facts
- InMed (INM, $5M market cap) entered into Amendment No. 1 to merge with private biotech Mentari Therapeutics in an all-stock reverse merger.
- Mentari's equity value is set at $125,000,000, implying extreme dilution for current INM shareholders relative to the $5M market cap.
- The amendment introduces a 'Company PIPE Amendment' to allow additional pre-closing financing, which will further dilute the exchange ratio for INM holders.
- A Nasdaq Reverse Split is planned before closing to maintain listing compliance.
- InMed will redomesticate from British Columbia to Nevada and rename to 'Mentari Therapeutics, Inc.' at closing.
- The S-4 registration statement was filed July 2, 2026, but has not yet been declared effective.
- Closing expected in Q4 2026, subject to shareholder approvals for both companies and SEC effectiveness.
Financial Impact
Mentari's equity value is $125M vs. InMed's current market cap of $5M. Existing INM shareholders will retain a minority stake after the reverse merger, with additional dilution possible from the PIPE amendment.
Risk Factors
- Merger may not close if shareholder approvals or SEC effectiveness are not obtained.
- Extreme dilution of INM common shares; current shareholders will own a tiny fraction of the combined company.
- Nasdaq delisting risk if reverse split is not approved or executed in time.
- Mentari's pipeline is preclinical/early clinical — no approved products or revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-077127 |
| Document: ea029728401ex2-2.htm | 0001213900-26-077127 |
| Document: ea029728401ex99-1.htm | 0001213900-26-077127 |
| Document: 0001213900-26-077127-index-headers.html | 0001213900-26-077127 |
| Document: 0001213900-26-077127-index.html | 0001213900-26-077127 |
| Document: 0001213900-26-077127.txt | 0001213900-26-077127 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 425 | $1.31 $1.39 | ▲ +6.11% | ▲ +6.61% | $1.33 (+1.53%) |
Jul 10, 2026 12w ago | 8-K | $1.57 $1.52 | ▲ +3.18% | ▲ +2.40% | $1.33 (+15.29%) |
Jul 2, 2026 13w ago | S-4 | $1.56 $1.66 | ▼ −6.41% | ▼ −5.48% | $1.33 (+14.74%) |
Jun 11, 2026 16w ago | Insider Cluster | $1.58 $1.49 | ▼ −5.70% | ▼ −6.13% | $1.33 (−15.82%) |
Jun 10, 2026 16w ago | 8-K | $1.51 $1.48 | ▼ −1.99% | ▼ −5.42% | $1.33 (−11.92%) |
May 19, 2026 19w ago | 425 | $1.60 $1.69 | ▲ +5.63% | ▲ +3.38% | $1.33 (−16.87%) |
May 19, 2026 19w ago | 8-K | $1.60 $1.69 | ▲ +5.63% | ▲ +3.38% | $1.33 (−16.87%) |
May 19, 2026 19w ago | 8-K | $1.60 $1.66 | ▼ −3.75% | ▼ −1.45% | $1.33 (+16.87%) |
Apr 27, 2026 22w ago | 8-K | $0.7010 $0.7480 | ▼ −6.70% | ▼ −5.01% | $1.33 (−89.73%) |
Apr 3, 2026 26w ago | 8-K | $0.6950 $0.7130 | ▲ +2.59% | ▼ −1.54% | $1.33 (+91.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access